(Q39770209)

English

Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

prostate cancer screening

1 reference

based on heuristic

inferred from title

2

object named as

Monique J Roobol

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Ingrid W van der Cruijsen-Koeter

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Mark F Wildhagen

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

T H van der Kwast

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

W J Kirkels

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Fritz H Schröder

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

0 references

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

68

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

615-620

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction

2 references

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Second round results of the Finnish population-based prostate cancer screening trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Three-year results of the Finnish prostate cancer screening trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

MISCAN: estimating lead-time and over-detection by simulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Interval Carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.015

7 January 2021

Identifiers

10.1016/J.UROLOGY.2006.03.015

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39770209&oldid=2090144745"